Skip to content
Screener

Globus Medical GMED Reportable Segment — Research and Development Employee Related Costs

Similar metrics at other companies

ImmunityBio, Inc. logo
IBRXReportable Segment — Other research and development costs
$8.47M+31.0%
MapLight Therapeutics, Inc. logo
MPLTEmployee Related — Research And Development Expense
$15.99M+127%
Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%
Alumis Inc. logo
ALMSSingle Reportable — Research And Development Personnel Related Costs
$26.07M+47.6%
Weave Communications logo
WEAVReportable Segment — Payroll and employee-related costs
$43.47M-1.2%
Beam Therapeutics logo
BEAMEmployee Related Expenses — Research And Development Expense
$32.87M+12.4%

Other financials

Income statement

See full
Revenue$789.6M+5.9%
Gross profit$548.2M+10.4%
Operating income$182.4M+140%
Net income$151.6M-25.3%
EPS (diluted)$1.10-26.2%

Balance sheet

See full
Cash & equivalents$507.7M+121%
Total debt$112.3M-7.6%
Total equity$4.8B+11.0%
Total assets$5.5B+10.6%

Cash flow

See full
Operating cash flow$209.7M+169%
CapEx$33.2M-28.8%
Free cash flow$176.6M+464%

Valuation

See full
Market cap$10.93B+52.9%
Enterprise value$10.54B+49.6%
P/E20.4×+0.4×
P/S3.5×+0.8×

Profitability

See full
Gross margin68.5%+5.8pp
Operating margin20.3%+9.6pp
Net margin17%+3.4pp
FCF margin24%+3.9pp

Returns & leverage

See full
Return on equity11.8%+3.2pp
Debt / equity0.0×
Current ratio4.6×+0.5×

Where this comes from

Reported directly by Globus Medical in its filing.

Tagged under the XBRL concept gmed:ResearchAndDevelopmentEmployeeRelatedCosts.

The source filing: Globus Medical’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054450
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales(210,505)(213,162)(413,494)(379,538)
Amortization of inventory fair value step-up (a)(5,967)(6,016)
Depreciation related to cost of sales(30,934)(29,636)(62,011)(58,609)
Research and development employee-related cost(26,126)(30,101)(53,463)(55,533)
Research and development other (b)(10,194)(9,852)(19,367)(17,483)
Selling, general and administrative employee-related cost(218,357)(237,372)(445,257)(426,353)
Selling, general and administrative other (c)(55,364)(59,258)(113,797)(104,881)
Provision for litigation(62)2,621(196)3,908

Item 1. Financial Statements

FAQ

What is Globus Medical's reportable segment — research and development employee related costs?
Globus Medical (GMED) reported reportable segment — research and development employee related costs of $26.13M in Q2 2026.
How has Globus Medical's reportable segment — research and development employee related costs changed year-over-year?
Globus Medical's reportable segment — research and development employee related costs decreased by 13.2% year-over-year, from $30.1M to $26.13M.
What does reportable segment — research and development employee related costs mean?
Captures the compensation, benefits, and stock-based compensation expenses for personnel directly involved in the research and development of new medical technologies. This is a primary driver of innovation and future product pipeline growth.

Ask your AI about Globus Medical's reportable segment — research and development employee related costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude